The Centers for Medicare & Medicaid Services (CMS) announces a new Medicare pilot program that provides access to certain glucagon-like peptide-1 (GLP-1) medications for weight loss at a cost of $50 per month. The initiative is designed to expand Medicare coverage beyond earlier use of these drugs for conditions such as diabetes, where some GLP-1 therapies were already available under Medicare for qualifying beneficiaries. Under the pilot, eligible Medicare beneficiaries can obtain specified GLP-1 drugs aimed at weight management for a reduced monthly price, compared with typical out-of-pocket costs. Reporting indicates the program could potentially reach a large number of people, with one outlet suggesting up to 14 million Medicare patients may be eligible, depending on the criteria used to determine eligibility for the pilot. The details of who qualifies, including specific Medicare beneficiary categories and any clinical or program requirements, are tied to CMS’s pilot structure and coverage rules. The JAMA Network report focuses on the program’s cost and CMS’s role in administering the pilot, while other reporting highlights potential scale and how weight loss coverage fits into Medicare’s existing approach to GLP-1 medications.